Literature DB >> 30718299

NK Cells Require Cell-Extrinsic and -Intrinsic TYK2 for Full Functionality in Tumor Surveillance and Antibacterial Immunity.

Natalija Simonović1, Agnieszka Witalisz-Siepracka1,2, Katrin Meissl1, Caroline Lassnig1,3, Ursula Reichart1,3, Thomas Kolbe3,4, Matthias Farlik5, Christoph Bock5, Veronika Sexl2, Mathias Müller1,3, Birgit Strobl6.   

Abstract

Tyrosine kinase 2 (TYK2) is a widely expressed receptor-associated kinase that is involved in signaling by a variety of cytokines with important immune regulatory activities. Absence of TYK2 in mice results in impaired NK cell maturation and antitumor activity, although underlying mechanisms are largely unknown. Using conditional ablation of TYK2 in NK cells we show that TYK2 is required for IFN-γ production by NK cells in response to IL-12 and for an efficient immune defense against Listeria monocytogenes Deletion of TYK2 in NK cells did not impact NK cell maturation and IFN-γ production upon NK cell activating receptor (actR) stimulation. Similarly, NK cell-mediated tumor surveillance was unimpaired upon deletion of TYK2 in NK cells only. In line with the previously reported maturation-associated Ifng promoter demethylation, the less mature phenotype of Tyk2-/- NK cells correlated with an increased CpG methylation at the Ifng locus. Treatment with the DNA hypomethylating agent 5-aza-2-deoxycytidine restored the ability of Tyk2-/- NK cells to produce IFN-γ upon actR but not upon IL-12 stimulation. NK cell maturation was dependent on the presence of TYK2 in dendritic cells and could be rescued in Tyk2-deficient mice by treatment with exogenous IL-15/IL-15Rα complexes. IL-15 treatment also rescued the in vitro cytotoxicity defect and the impaired actR-induced IFN-γ production of Tyk2-/- NK cells. Collectively, our findings provide the first evidence, to our knowledge, for a key role of TYK2 in the host environment in promoting NK cell maturation and antitumor activity.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30718299      PMCID: PMC6398083          DOI: 10.4049/jimmunol.1701649

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  80 in total

1.  IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.

Authors:  Sigrid Dubois; Jennifer Mariner; Thomas A Waldmann; Yutaka Tagaya
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

Review 2.  NK cell recognition.

Authors:  Lewis L Lanier
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

3.  A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development.

Authors:  Eva Eckelhart; Wolfgang Warsch; Eva Zebedin; Olivia Simma; Dagmar Stoiber; Thomas Kolbe; Thomas Rülicke; Mathias Mueller; Emilio Casanova; Veronika Sexl
Journal:  Blood       Date:  2010-12-02       Impact factor: 22.113

Review 4.  Innate or adaptive immunity? The example of natural killer cells.

Authors:  Eric Vivier; David H Raulet; Alessandro Moretta; Michael A Caligiuri; Laurence Zitvogel; Lewis L Lanier; Wayne M Yokoyama; Sophie Ugolini
Journal:  Science       Date:  2011-01-07       Impact factor: 47.728

5.  The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ.

Authors:  Feng Ma; Sheng Xu; Xingguang Liu; Qian Zhang; Xiongfei Xu; Mofang Liu; Minmin Hua; Nan Li; Hangping Yao; Xuetao Cao
Journal:  Nat Immunol       Date:  2011-07-24       Impact factor: 25.606

6.  Role of NK1.1+ cells in experimental listeriosis. NK1+ cells are early IFN-gamma producers but impair resistance to Listeria monocytogenes infection.

Authors:  H C Teixeira; S H Kaufmann
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

7.  Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design.

Authors:  Woo Dae Jang; Jun-Tae Kim; Hoon Young Son; Seung Yeon Park; Young Sik Cho; Tae-sung Koo; Hyuk Lee; Nam Sook Kang
Journal:  Bioorg Med Chem Lett       Date:  2015-07-21       Impact factor: 2.823

Review 8.  Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene.

Authors:  Nicole R Leitner; Agnieszka Witalisz-Siepracka; Birgit Strobl; Mathias Müller
Journal:  Cytokine       Date:  2015-11-26       Impact factor: 3.861

9.  Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance.

Authors:  Raimund M Vielnascher; Eva Hainzl; Nicole R Leitner; Michael Rammerstorfer; David Popp; Agnieszka Witalisz; Rita Rom; Marina Karaghiosoff; Thomas Kolbe; Simone Müller; Thomas Rülicke; Caroline Lassnig; Birgit Strobl; Mathias Müller
Journal:  Transgenic Res       Date:  2014-04-03       Impact factor: 2.788

10.  In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity.

Authors:  Michaela Prchal-Murphy; Agnieszka Witalisz-Siepracka; Karoline T Bednarik; Eva Maria Putz; Dagmar Gotthardt; Katrin Meissl; Veronika Sexl; Mathias Müller; Birgit Strobl
Journal:  Oncoimmunology       Date:  2015-05-26       Impact factor: 8.110

View more
  7 in total

1.  Identifying RNA Biomarkers and Molecular Pathways Involved in Multiple Subtypes of Uveitis.

Authors:  James T Rosenbaum; Christina A Harrington; Robert P Searles; Suzanne S Fei; Amr Zaki; Sruthi Arepalli; Michael A Paley; Lynn M Hassman; Albert T Vitale; Christopher D Conrady; Puthyda Keath; Claire Mitchell; Lindsey Watson; Stephen R Planck; Tammy M Martin; Dongseok Choi
Journal:  Am J Ophthalmol       Date:  2021-01-24       Impact factor: 5.488

Review 2.  STAT1 and Its Crucial Role in the Control of Viral Infections.

Authors:  Manlio Tolomeo; Andrea Cavalli; Antonio Cascio
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

3.  Tyk2 is a tumor suppressor in colorectal cancer.

Authors:  Stefan Moritsch; Bernadette Mödl; Irene Scharf; Lukas Janker; Daniela Zwolanek; Gerald Timelthaler; Emilio Casanova; Maria Sibilia; Thomas Mohr; Lukas Kenner; Dietmar Herndler-Brandstetter; Christopher Gerner; Mathias Müller; Birgit Strobl; Robert Eferl
Journal:  Oncoimmunology       Date:  2022-09-26       Impact factor: 7.723

Review 4.  TYK2 in Immune Responses and Treatment of Psoriasis.

Authors:  Lin Shang; Jiali Cao; Siqi Zhao; Jingya Zhang; Yanling He
Journal:  J Inflamm Res       Date:  2022-09-16

Review 5.  Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Authors:  Klara Klein; Dagmar Stoiber; Veronika Sexl; Agnieszka Witalisz-Siepracka
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

Review 6.  JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation.

Authors:  Dagmar Gotthardt; Jana Trifinopoulos; Veronika Sexl; Eva Maria Putz
Journal:  Front Immunol       Date:  2019-11-12       Impact factor: 7.561

7.  STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity.

Authors:  Katrin Meissl; Natalija Simonović; Lena Amenitsch; Agnieszka Witalisz-Siepracka; Klara Klein; Caroline Lassnig; Ana Puga; Claus Vogl; Andrea Poelzl; Markus Bosmann; Alexander Dohnal; Veronika Sexl; Mathias Müller; Birgit Strobl
Journal:  Front Immunol       Date:  2020-09-11       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.